Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | TERT | O14746 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL3583425 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1MAPTPOLBTERT | |
| SCHEMBL1452 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1MAPTTERTMEN1 | |
| SCHEMBL6338203 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTPOLBTERT | |
| SCHEMBL10733902 | 0.81 | MAPT (0.56) | SMN1; SMN2ALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL6365491 | 0.81 | SMN1; SMN2 (0.82) | SMN1; SMN2MAPTPOLBTERTMEN1 | |
| SCHEMBL28038421 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL7847021 | 0.80 | SMN1; SMN2 (0.90) | SMN1; SMN2MAPTTERTMEN1KMT2A | |
| SCHEMBL6443705 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1MAPTTERTMEN1 | |
| SCHEMBL5411887 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1MAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| CN-1028758-C | Pyrazolopyrimidinone antianginal agents | PFIZER (US) | 1995-06-07 | — | — | CN | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
| CN-1057464-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1992-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | SMN1; SMN2 2913/4885ALDH1A1 1248/4885MAPT 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.